Skip to main content
SpringerLink
Log in

Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness

  • Research papers
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

In order to invade and spread cancer cells must degrade extracellular matrix proteins. This degradation is catalysed by the concerted action of several enzymes, including the serine protease plasmin. Several experimental studies have shown that inhibition of plasmin formation reduces cancer cell invasion and metastasis, indicating a critical role of this proteolytic pathway in these processes. In order to further study the role of plasmin in cancer progression, we have characterized urokinase-type plasminogen activator (uPA) mediated plasmin formation in three human breast cancer cell lines. Using monoclonal antibodies against uPA and its receptor uPAR, we have investigated the contribution of uPA and uPAR to invasive capacity in an in vitro invasion assay. MDA-MB-231 BAG cells were found to express high protein levels of uPA, uPAR and PAI-1. MDA-MB-435 BAG cells produced low amounts of uPA, PAW and moderate amounts of uPAR, whereas MCF-7 BAG cells showed low levels of uPA, uPAR and PAM protein. In a plasmin generation assay MDA-MB-231 BAG cells were highly active in mediating plasmin formation, which could be abolished by adding either an anticatalytic monoclonal antibody to uPA (clone 5) or an anti-uPAR monoclonal antibody (clone R3), which blocks binding of uPA to uPAR. The two other cell lines lacked the capacity to mediate plasmin formation. In the Matrigel invasion assay the cells showed activity in this order: MCF-7 BAG < MDA-MB-435 BAG < MDA-MB-231 BAG. Testing MDA-MB-231 BAG cells in the Matrigel invasion assay revealed that invasion could be inhibited in a dose-dependent manner either by the clone 5 uPA antibody or by the clone R3 uPAR antibody, suggesting that the cell surface uPA system is actively involved in this invasive process. It is concluded that these three cell lines constitute a valuable model system for in vitro studies of the role of cell surface uPA in cancer cell invasion and has application in the search for novel compounds which inhibit mechanisms involved in uPA-mediated plasmin generation on cancer cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hollas W, Blasi F and Boyd D, 1991, Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res, 51, 3690–5.

    Google Scholar 

  2. Ossowski L, 1988, In vivo invasion of modified chorioallantoic membrane by tumor cells: The role of cell surface-bound urokinase. J Cell Biol, 107, 2437–45.

    Google Scholar 

  3. Quax PHA, Pedersen N, Masucci MT, et al. 1991, Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regulation, 2, 793–803.

    Google Scholar 

  4. Ossowski L, Clunie G, Masucci MT and Blasi F, 1991, In vivo paracrine interaction between urokinase and its receptor: Effect on tumor invasion. J Cell Biol, 115, 1107–12.

    Google Scholar 

  5. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD and Stetler-Stevenson WG, 1991, Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst, 83, 775–9.

    Google Scholar 

  6. Ossowski L and Reich E, 1983, Antibodies to plasminogen activator inhibit human tumor metastasis. Cell, 35, 611–19.

    Google Scholar 

  7. Ossowski L, Russo-Payne H and Wilson EL, 1991, Inhibition of urokinase-type plasminogen activator by antibodies: The effect on dissemination of a human tumor in the nude mouse. Cancer Res, 51, 274–81.

    Google Scholar 

  8. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA and Levinson AD, 1993, Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA, 90, 5021–25.

    Google Scholar 

  9. Kobayashi H, Gotoh J, Fujie M, Shinohara H, Moniwa N and Terao T, 1994, Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within the growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int J Cancer, 57, 727–33.

    Google Scholar 

  10. Kook YH, Adamski J, Zelent A and Ossowski L, 1994, The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J, 17, 3983–91.

    Google Scholar 

  11. Schultz RM, Silberman S, Persky B, Bajkowski AS and Carmichael DF, 1988, Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res, 48, 5539–5545.

    Google Scholar 

  12. DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE and Taylor SM, 1992, Inhibition of metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res, 52, 701–8.

    Google Scholar 

  13. Prendiville J, Crowther D, Thatcher N, et al. 1993, A phase I study of intraveneous bryostatin-1 in patients with advanced cancer. Br J Cancer, 68, 418–24.

    Google Scholar 

  14. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS and Skriver L, 1985, Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res, 44, 139–266.

    Google Scholar 

  15. Danø K, Nielsen LS, Pyke C and Kellerman GM, 1988, Plasminogen activators and neoplasia. In: Kluft C, ed. Tissue-type plasminogen activator (t-PA): Physiological and clinical aspects. Boca Raton: CRC Press, pp. 19–46.

    Google Scholar 

  16. Roldan AL, Cubellis MV, Masucci MT, et al. 1990, Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J, 9, 467–74.

    Google Scholar 

  17. Andreasen PA, Georg B, Lund LIZ, Riccio A and Stacey SN, 1990, Plasminogen activator inhibitors: Hormonally regulated serpins. Molec Cell Endocr, 68, 1–19.

    Google Scholar 

  18. Ellis V, Behrendt N and Danó K, 1991, Plasminogen activation by receptor-bound urokinase: A kinetic study with both cell-associated and isolated receptor. J Biol Chem, 266, 12752–8.

    Google Scholar 

  19. Ellis V, Scully MF and Kakkar VV, 1989, Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem, 264, 2185–8.

    Google Scholar 

  20. Ellis V, Wun TC, Behrendt N, Renne E and Danø K, 1990, Inhibition of receptor-bound urokinase by plasminogen activator inhibitors. J Biol Chem, 265, 9904–8.

    Google Scholar 

  21. Cubellis MV, Wun TC and Blasi F, 1990, Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J, 9, 1079–85.

    Google Scholar 

  22. Estreicher A, Mühlhauser J, Carpentier J-L, Orci L and Vassali JD, 1990, The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol, 111, 783–92.

    Google Scholar 

  23. Olson D, Pöllänen J, Heyer-Hansen G, et al. 1992, Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem, 267, 9129–9133.

    Google Scholar 

  24. Nykjær A, Petersen CM, Møller B, et al. 1992, Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem, 267, 14543–6.

    Google Scholar 

  25. Murphy G, Ward R, Gavrilovic J and Atkinson S, 1992, Physiological mechanisms for metalloproteinase activation. In: Birkedal-Hansen H, Werb Z, Welgus H, Van Wart H, eds. Matrix metalloproteinases and inhibitors. Gustav Fisher Verlag: Stuttgart, pp. 245–55.

    Google Scholar 

  26. Lyons RM, Gentry LE, Purchio AF and Moses HL, 1990, Mechanism of activation of latent recombinant transforming growth factor 1 by plasmin. J Cell Biol, 110, 1361–7.

    Google Scholar 

  27. Sato Y and Rifkin DB, 1989, Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-β1-like molecule by plasmin during co-culture. J Cell Biol, 109, 309–15.

    Google Scholar 

  28. Campbell PG, Novak JF, Yanosick TB and McMaster JH, 1992, Involvement of plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology, 130, 1401–12.

    Google Scholar 

  29. Saksela O and Rifkin DB, 1990, Release of basic fibroblast growth factor-heparin sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol, 110, 767–75.

    Google Scholar 

  30. Brünner N, Thompson EW, Spang-Thomsen M, Rygaard J, Danø K and Zwiebel JA, 1992, LacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis. Eur J Cancer, 28A, 1989–95.

    Google Scholar 

  31. Price J, Turner D and Cepko C, 1987, Lineage analysis in the vertebrate system by retrovirus-mediated gene transfer. Proc Natl Acad Sci USA, 84, 156–60.

    Google Scholar 

  32. Mosmann T, 1983, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Meth, 65, 55–63.

    Google Scholar 

  33. Camiolo SM, Suita MR and Madeja JM, 1982, Improved medium for extraction of plasminogen activator from tissue. Prep Biochem, 12, 297–305.

    Google Scholar 

  34. Ronne E, Heyer-Hansen G, Brünner N, et al. 1995, Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat, 33, 199–207.

    Google Scholar 

  35. Ronne E, Behrendt N, Ploug M, et al. 1994, Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay. J Immunol Meth, 167, 91–101.

    Google Scholar 

  36. Rosenquist C, Thorpe SM, Danø K and Grøndahl-Hansen J, 1993, Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue. Breast Cancer Res Treat, 28, 223–30.

    Google Scholar 

  37. Grendahl-Hansen J, Christensen IJ, Rosenquist C, et al. 1993, High levels of urokinase-type plasminogen activator and its inhibitor PAM in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res, 53, 2513–21.

    Google Scholar 

  38. Andreasen PA, Nielsen LS, Kristensen P, Grøndahl-Hansen J, Skriver L and Dana K, 1986, Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem, 261, 7644–51.

    Google Scholar 

  39. Nielsen LS, GrØndahl-Hansen J, Andreasen PA, Skriver L, Zeuthen J and Danø K, 1986, Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies. J Immunoassay, 7, 209–28.

    Google Scholar 

  40. Behrendt N, Rønne E, Ploug M, et al. 1990, The human receptor for urokinase plasminogen activator. NH2-terminal amino acid and glycosylation variants. J Biol Chem, 265, 6453–60.

    Google Scholar 

  41. Ellis V, Behrendt N and Danø K, 1993, Cellular receptor for urokinase-type plasminogen activator: Function in cell-surface proteolysis. Meth Enzym, 223, 223–33.

    Google Scholar 

  42. Ronne E, Behrendt N, Ellis V, Ploug M, Danø K and Høyer-Hansen G, 1991, Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett, 288, 233–6.

    Google Scholar 

  43. Repesh LA, 1989, A new in vitro assay for quantitating tumor cell invasion. Invasion and Metastasis, 9, 192–208.

    Google Scholar 

  44. Nielsen LS, Andreasen PA, Grøndahl-Hansen J, Huang JY, Kristensen P and Danø K, 1986, Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells — inhibitor neutralization and one-step affinity purification. Thrombosis and Haemostasis, 55, 206–12.

    Google Scholar 

  45. Keijer J, Linders M, van Zonneveld AJ, Ehrlich HJ, de Boer JP and Pannekoek H, 1991, The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: Localization of interaction sites and physiologic relevance. Blood, 78, 401–9.

    Google Scholar 

  46. Solberg H, Romer J, Brünner N, et al. 1994, A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer, 58, 877–81.

    Google Scholar 

  47. Rose DP, Connolly JM and Liu XH, 1994, Effects of linoleic acid on the growth and metastasis of two human breast cancer cell lines in nude mice and the invasive capacity of these cell lines in vitro. Cancer Res, 54, 6557–62.

    Google Scholar 

  48. Busso N, Belin D, Failly-Crépin C and Vassalli JD, 1987, Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231. Cancer Res, 15, 364–70.

    Google Scholar 

  49. Romer J, Pyke C, Lund LR, et al. 1994, Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion. Int J Cancer, 57, 553–60.

    Google Scholar 

  50. Azzam HS, Arand G, Lippman ME and Thompson EW, 1993, Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Nail Cancer Inst. 85, 1758–64.

    Google Scholar 

  51. Pyke C, Ralfkiær E, Huhtala P, Hurskainen T, Danø K and Tryggvason K, 1992, Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenase in human skin cancers by in situ hybridization. Cancer Res, 52, 1336–41.

    Google Scholar 

  52. Pyke C, Graem N, Ralfkiær E, et al. 1993, Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res, 53, 1911–15.

    Google Scholar 

  53. Thompson EW, Paik S, Brünner N, et al. 1992, Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Phys, 150, 534–44.

    Google Scholar 

  54. Pourreau-Schneider N, Delori P, Boutière B, et al. 1989, Modulation of plasminogen activator systems by matrix components in two breast cancer cell lines: MCF-7 and MDA-MB-231. J Natl Cancer Inst, 81, 259–66.

    Google Scholar 

  55. Danø K, Behrendt N, Brünner N, Ellis V, Ploug M and Pyke C, 1994, The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis, 8, 189–203.

    Google Scholar 

  56. Pedersen H, Brünner N, Francis D, et al. 1994, Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res, 54, 4671–5.

    Google Scholar 

  57. Ganesh S, Sier CFM, Heerding MM, Griffioen G, Lamers CB and Verspaget HW, 1994, Urokinase receptor and colorectal cancer survival. The Lancet, 344, 401–2.

    Google Scholar 

  58. Grøndahl-Hansen J, Peters HA, van Putten WLJ, et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res, in press.

  59. Høyer-Hansen G, Ronne E, Solberg H, et al. 1992, Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem, 267, 18224–9.

    Google Scholar 

  60. Ploug M, Eriksen J, Plesner T, Hansen NE and Danø K, 1992, A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. Eur J Biochem, 208, 397–404.

    Google Scholar 

  61. Pedersen N, Schmitt M, Ronne E, et al. 1993,A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest, 92, 2160–7.

    Google Scholar 

  62. Duggan C, Maguire T, McDermott E, O'Higgins H, Fennelly JJ and Duffy MJ, 1995, Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer, 61, 597–600.

    Google Scholar 

  63. Nekarda N, Schmitt M, Ulm K, et al. 1994, Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res, 54, 2900–7.

    Google Scholar 

  64. Kuhn W, Pache L, Schmalfeldt B, et al. 1994, Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol, 55, 401–9.

    Google Scholar 

  65. Pyke C, Kristensen P, Ralfkiær E, Eriksen J and Danø K, 1991, The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res, 51, 4067–71.

    Google Scholar 

  66. Pappot H, Gârdsvoll H, Romer J, et al. 1995, Plasminogen activator inhibitor type 1 in cancer: Therapeutic and prognostic implications. Biol Chem Hoppe-Seyler, 376, 259–67.

    Google Scholar 

  67. Liu G, Shuman MA and Cohen RL, 1995, Co-expression of urokinase, urokinase receptor and PAI-I is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer, 60, 501–6.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Finsen Laboratory, Strandboulevarden 49, Copenhagen, Denmark

    Claus Holst-Hansen, Bente Johannessen, Gunilla Hoyer-Hansen, John Romer & Nils Brünner

  2. Emmanuel Kaye Building, Thrombosis Research Institute, London, UK

    Vincent Ellis

Authors
  1. Claus Holst-Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bente Johannessen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gunilla Hoyer-Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John Romer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vincent Ellis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nils Brünner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holst-Hansen, C., Johannessen, B., Hoyer-Hansen, G. et al. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metast 14, 297–307 (1996). https://doi.org/10.1007/BF00053903

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00053903

Keywords

Search

Navigation